# Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer

> **NCT01356368** · PHASE2 · TERMINATED · sponsor: **National Guard Health Affairs** · enrollment: 3 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cisplatin, Gemzar, Docetaxel, Alimta

## Key facts

- **NCT ID:** NCT01356368
- **Lead sponsor:** National Guard Health Affairs
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** slow accrual rate
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356368, "Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01356368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*